Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
49
Views
17
CrossRef citations to date
0
Altmetric
Case Report

Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Yanmei Peng1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
,
Huijuan Cui2 Department of Oncology, China-Japan Friendship Hospital, ChaoyangCorrespondence[email protected]
,
Zhe Liu3 Department of Oncology, Beijing Chest Hospital, Tongzhou, Beijing, People’s Republic of China
,
Daiwei Liu1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
,
Fan Liu1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
,
Yazhong Song1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
,
Hua Duan1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
,
Yuqin Qiu1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
&
Qiang Li1 Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine
 show all
Pages 2289-2295 | Published online: 26 Apr 2017

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Shen-Cun Fang, Wen Huang, Ying-Ming Zhang, Hai-Tao Zhang & Wei-Ping Xie. (2019) Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. OncoTargets and Therapy 12, pages 985-992.
Read now
Jin-min Xue, Manirakiza Astère, Mao-xi Zhong, Han Lin, Jin Shen & Yu-xi Zhu. (2018) Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis. OncoTargets and Therapy 11, pages 6119-6128.
Read now
Deze Zhao, Helei Hou & Xiaochun Zhang. (2018) Progress in the treatment of solid tumors with apatinib: a systematic review. OncoTargets and Therapy 11, pages 4137-4147.
Read now
Xiaofen Li, Xia Li, Xuefeng Fang & Ying Yuan. (2018) Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. OncoTargets and Therapy 11, pages 4047-4050.
Read now
Hua Duan, Yanmei Peng, Huijuan Cui, Yuqin Qiu, Qiang Li, Jingyi Zhang, Wen Shen, Chenyao Sun & Chufan Luo. (2018) Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report. OncoTargets and Therapy 11, pages 2303-2309.
Read now

Articles from other publishers (12)

Rizwan Qureshi, Syed Abdullah Basit, Jawwad A. Shamsi, Xinqi Fan, Mehmood Nawaz, Hong Yan & Tanvir Alam. (2022) Machine learning based personalized drug response prediction for lung cancer patients. Scientific Reports 12:1.
Crossref
Xiao Xiao Li. (2022) Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report. American Journal of Therapeutics 29:2, pages e269-e271.
Crossref
Milo Gatti, Emanuel Raschi, Elisabetta Poluzzi, Cristian Martignani, Stefania Salvagni, Andrea Ardizzoni & Igor Diemberger. (2020) The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. Current Heart Failure Reports 17:6, pages 365-383.
Crossref
Jian Li, Xiwen Tong & Hongtao Li. (2020) Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer. Indian Journal of Cancer 57:1, pages 13.
Crossref
Nazila Fathi Maroufi, Mohammad Reza Rashidi, Vahid Vahedian, Maryam Akbarzadeh, Amir Fattahi & Mohammad Nouri. (2020) Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sciences 241, pages 117106.
Crossref
Ping Fang, Liqin Zhang, Xianru Zhang, Jiawen Yu, Jun Sun, Qi-an Jiang, Mingbao Zha, Anastasia P. Nesterova & Hongbao Cao. (2019) Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial. Scientific Reports 9:1.
Crossref
Jin Liu, Yulong Zheng & Nong Xu. (2019) Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer. Medicine 98:5, pages e14328.
Crossref
Yuan-Peng Wu, Ji-Jin Wu, Shu-Mei Tian, Tao Jin, Chan Li & Ke Xie. (2019) Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC. Medicine 98:1, pages e13924.
Crossref
Di Wu, Li Liang, Ligong Nie, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Tao Xin & Jian Fang. (2018) Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. Asia-Pacific Journal of Clinical Oncology 14:6, pages 446-452.
Crossref
Dexiang Yang, Ranran Dai, Qi Zhang & Ping Fang. (2018) Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi Journal of Biological Sciences 25:5, pages 888-894.
Crossref
Miaomiao Gou, Haiyan Si, Yong Zhang, Niansong Qian, Zhikuan Wang, Weiwei Shi & Guanghai Dai. (2018) Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Scientific Reports 8:1.
Crossref
. (2017) Apatinib/dabigatran etexilate/erlotinib. Reactions Weekly 1656:1, pages 61-61.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.